Owens & Minor Inc. 2025 Annual Report: A Year of Transformation and Challenges

Owens & Minor's financial results for 2025 show a net loss per share from continuing operations of $(1.34), a significant recovery from $(4.57) in 2024. This improvement can be attributed to several factors, notably:

However, these gains were somewhat offset by substantial costs associated with the termination of the Rotech acquisition, which incurred an $80 million transaction breakage fee, along with increased costs of net revenue and intangible amortization.

For the year ending December 31, 2025, Owens & Minor reported a net income of $(1.10 billion), which included:

The operating environment was challenging, with a notable impact from a commercial payor's contract termination that affected $322 million or 12% of net revenue.

On December 31, 2025, Owens & Minor completed the sale of its Products & Healthcare Services (P&HS) business to Dominion Healthcare Acquisition Corporation for $375 million in cash. This strategic move is expected to allow the company to focus on growth areas while retaining a 5% equity interest in the sold segment.

The planned acquisition of Rotech Healthcare Holdings was mutually terminated in June 2025, resulting in a cash payout of $80 million. This decision reflects the company’s strategic recalibration in response to market conditions.

The revenue generated in 2025 showcased the company's diverse product offerings and customer base. The following pie charts illustrate the distribution of revenue by products, major customers, and geography.

The growth in revenue segments was highlighted by notable increases in categories such as sleep therapy (5.28% growth) and urology (8.31% growth), while diabetes remained a robust segment, amassing $783.3 million in revenue.

As of December 31, 2025, Owens & Minor’s balance sheet reflected total assets of $2.45 billion, with significant liabilities amounting to $2.91 billion. The company's equity stood at $(460.9 million), signifying a challenging financial position post-divestiture.

Despite the challenges, the company reported a net change in cash of $232.6 million for the year, aided by cash inflows from the sale of the P&HS business. However, cash used for operating activities reflected a net loss, highlighting the ongoing need for operational efficiencies.

Owens & Minor's Board of Directors authorized a share repurchase program of up to $100 million over two years, with $10 million spent on repurchasing 2 million shares in 2025. This move indicates confidence in the company's future trajectory.

The company also faces ongoing challenges with contractual obligations and liquidity management, as it continues to navigate the complexities of the healthcare market.

2025 was a pivotal year for Owens & Minor, characterized by significant operational shifts, strategic divestitures, and improvements in financial performance metrics. As the company embarks on this new chapter under the Accendra Health brand, stakeholders will be keen to observe how these strategic decisions will translate into sustainable growth and operational stability in the coming years.